Drug Profile
Research programme: diabetes therapeutics - NGM Biopharmaceuticals/JDRF
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NGM Biopharmaceuticals
- Developer JDRF; NGM Biopharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Type-1 diabetes mellitus in USA
- 03 Jan 2013 Early research in Type-1 diabetes mellitus in USA (unspecified route)